Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma
Open Access
- 29 May 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 45 (8) , 1038-1071
Abstract
Background: Intrahepatic cholangiocarcinoma (ICC) is a challenging cancer with an increasing incidence. The Phase III TOPAZ‐1/KEYNOTE‐966 study demonstrated chemo‐immunotherapy (CIT) as a significant advancement, potentially replacing traditional chemotherapy for advanced biliary tract cancer. Ferroptosis is a crucial process that affects cancer cell survival and therapy resistance. Although AKT hyperactivation is prevalent in numerous cancers, including ICC, its role in ferroptosis resistance remains unclear. This study explored whether targeting ferroptosis can enhance CIT response rates, specifically in ICC patients with AKT hyperactivation. Methods: In vivo metabolic CRISPR screening in a Kras G12D /Tp53 −/− ICC mouse model was used to identify primary regulators of ferroptosis during CIT (gemcitabine, cisplatin, and anti‐mouse programmed cell death 1 ligand 1). Phosphoenolpyruvate carboxykinase 1 (PCK1) was assessed for its role in ferroptosis and treatment resistance in preclinical models under AKT activation levels. Molecular and biochemical techniques were used to explore PCK1‐related resistance mechanisms in AKT‐hyperactivated ICC. Results: Under AKT hyperactivation condition, phosphorylated PCK1 (pPCK1) promoted metabolic reprogramming, enhancing ubiquinol and menaquinone‐4 synthesis through the mevalonate (MVA) pathway. This cascade was mediated by the pPCK1‐pLDHA‐SPRINGlac axis. Inhibiting PCK1 phosphorylation or using simvastatin significantly augmented CIT efficacy in preclinical models. Clinical data further indicated that phosphorylated AKT (pAKT)‐pPCK1 levels might serve as a biomarker to predict CIT response in ICC. Conclusion: This study identified the pAKT‐pPCK1‐pLDHA‐SPRINGlac axis as a novel mechanism driving ferroptosis resistance in AKT‐hyperactivated ICC by associating glycolytic activation with MVA flux reprogramming. Targeting this axis, potentially through statin‐based therapies, may offer a strategy to sensitize ICC cells to ferroptosis and improve treatment outcomes.Keywords
Funding Information
- National Natural Science Foundation of China (81874149)
- National Natural Science Foundation of China (82171834)
- National Natural Science Foundation of China (82303832)
- National Natural Science Foundation of China (82403618)
- National Natural Science Foundation of China (81874149)
- National Natural Science Foundation of China (82171834)
- National Natural Science Foundation of China (82303832)
- National Natural Science Foundation of China (82403618)
- China Postdoctoral Science Foundation (2024M761039)
This publication has 76 references indexed in Scilit:
- Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapyCancer Cell, 2024
- Metabolic regulation of homologous recombination repair by MRE11 lactylationCell, 2023
- Statins associate with lower risk of biliary tract cancers: A systematic review and meta‐analysisCancer Medicine, 2022
- Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint InhibitorsAdvanced Science, 2022
- CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4Cancer Cell, 2022
- In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy targetCell, 2021
- Metabolic modeling of single Th17 cells reveals regulators of autoimmunityCell, 2021
- PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesisCell Reports, 2021
- Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver CancerCancer Cell, 2019
- Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine: method validation, demonstration of using a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standardRapid Communications in Mass Spectrometry, 2003